Boostrix 0.5ml Vaccine

Prevention of Tetanus
Prevention of Pertussis
Prevention of Diphtheria

Undesired symptoms or responses vary from individual to individual as the human body reacts differently to the Boostrix 0.5ml Vaccine, but they disappear naturally within a few days as the body adjusts to the vaccine, which requires no medical attention. In case these symptoms don't go away and you face severe side effects, then immediately consult your doctor or medical team. Some of the common side effects of the Boostrix 0.5ml Vaccine are: Fatigue Headache Gastrointestinal problem Fever loss of appetite Nausea Pain, redness or swelling at injection site anaphylaxis in some severe cases.

Undesired symptoms or responses vary from individual to individual as the human body reacts differently to the Boostrix 0.5ml Vaccine, but they disappear naturally within a few days as the body adjusts to the vaccine, which requires no medical attention. In case these symptoms don't go away and you face severe side effects, then immediately consult your doctor or medical team. Some of the common side effects of the Boostrix 0.5ml Vaccine are: Fatigue Headache Gastrointestinal problem Fever loss of appetite Nausea Pain, redness or swelling at injection site anaphylaxis in some severe cases.

Boostrix 0.5ml Vaccine is used as a booster dose against the bacterial diseases pertussis, tetanus, and diphtheria for people 10 years or older. It is given into the deltoid muscle of the upper arm. It is an intramuscular injection. Do not use the same injection or syringe for another vaccine, as there is are chance of interacting. Always check the vial of vaccine before using it for discoloration or any kind of particulate matter, and shake well for uniform mixing of the product. Adults, adolescents, and pregnant women in 27 and 36 weeks of gestation can take Boostrix 0.5ml Vaccine. It should be given intravenously or subcutaneously, and stored at 2℃ to 8 ℃.

DeSilva, M., Munoz, F. M., Mcmillan, M., Kawai, A. T., Marshall, H., Macartney, K. K., & Brighton Collaboration Congenital Anomalies Working Group. (2024). Congenital anomalies: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine, 34(49), 6015-6026.
Kuznetsova, A., Ceregido, M. A., Jourquin, A., Campora, L., & Tavares-Da-Silva, F. (2023). Fourteen years of the pregnancy registry on maternal immunization with a reduced-antigen-content tetanus-diphtheria-acellular pertussis (Tdap) vaccine. Vaccine, 40(6), 904-911.
McCormack, P. L. (2024). Reduced-Antigen, Combined Diphtheria, Tetanus and Acellular Pertussis Vaccine, Adsorbed (Boostrix®): A Review of its Properties and Use as a Single-Dose Booster Immunization. Drugs, 72(13), 1765-1791.
Weston, W. M., Friedland, L. R., Wu, X., & Howe, B. (2025). Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix®): results of two randomized trials. Vaccine, 30(9), 1721-1728.
Zhu, F., Zhang, S., Hou, Q., Zhang, Y., Xu, Y., Ma, X., & Bock, H. L. (2020). Booster vaccination against pertussis in Chinese children at six years of age using reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (Boostrix™). Human Vaccines, 6(3), 263-269.